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Previews
unwanted mutations in other genes. Crucially, the tre-New Compounds By Combining
mendous progress that researchers have achieved in“Modern” Genomics elucidating and manipulating the biosynthetic pathways
and “Old-Fashioned” Mutasynthesis of secondary metabolites can now be used to make
“surgical” interventions which affect only one desired
pathway, specifically blocking the production of a cer-
tain building block or structural feature of a particularMolecular approaches enable the identification of
corresponding compound. Thus, genetics can be usedgenes that operate in natural product biosynthetic
to generate mutants where the synthesis of a specificpathways. Microbes containing mutations in those
precursor is prevented, and these mutant strains cangenes can be fed alternative precursors, generating
subsequently be used for mutasynthesis, a better termderivatives of complex natural products, which may
for which may be “precursor-directed biosynthesis.”not be obtainable by chemical methods.
The use of precursor-directed biosynthesis promises
to be particularly useful for modifying the chemical back-Natural products exhibit an enormous source for drug
bones of highly complex molecules like the pharmaceu-leads, which is exemplified by the finding that 60% of
tically important type I polyketides (PKS) (e.g., erythro-all new antibacterial and anticancer drugs approved be-
mycin) or nonribosomally synthesized peptides (e.g.,tween 1983 and 1994 were derived from natural com-
vancomycin). The backbones of both of these compoundspounds [1]. However, before these natural compounds
are synthesized in an assembly-line manner by multimod-are commercially developed, they usually have to be
ular enzymes and are subsequently modified by tailoringmodified to generate a collection of chemically related
enzymes [7]. Although the application of precursor-structures. Optimization of these drug leads can be
directed biosynthesis has been demonstrated for PKS-achieved using modern organic chemistry, but this ap-
type antibiotics [8], such experiments have not beenproach is limited for complex, high molecular weight
reported for nonribosomally synthesized peptides untilnatural products that contain a great number of reactive
recently.groups, some of which require protection during the
An interesting feature of metabolites that are synthe-reaction process. Even though Nicolaou and others have
sized by nonribosomal peptide synthetases is that theyconvincingly demonstrated that highly complicated mol-
often contain nonproteinogenic amino acids. Recently,ecules such as vancomycin, everninomycin, or epothi-
some of the mechanisms for syntheses of amino acidslone can be synthesized de novo [2], alternative tech-
such as 3,5-dihydroxyphenylglycine (DPG) [9], -hydrox-niques are required for the production of the larger
ylated amino acids [10, 11], and 4-hydroxyphenylglycineamounts of compounds that are needed for pharmaceu-
(HPG) [12] have been elucidated, and the genes involvedtical purposes.
in the synthesis of these and further nonproteinogenicIn 1985, Hopwood and colleagues demonstrated a
amino acids have been identified and functionally char-new approach for lead optimization by using genes from
acterized. These genes are part of a particular biosyn-different natural product-producing microbes to create
thetic gene cluster. This information make it easier fornovel hybrid compounds [3]. Madduri and coworkers
researchers to analyze new biosynthetic gene clusters:proceeded to adapt this combinatorial biosynthetic ap-
after a cluster has been identified and the putative func-proach for an industrially relevant compound in 1998 [4].
tion has been assigned in silico by using bioinformaticBy introducing a desoxysugar biosynthesis gene into the
tools, the respective genes can easily be identified anddoxorubicin producer S. peucetius, the authors generated
directly be cloned for manipulation. This knowledge hasa strain that directly synthesized one of the most important
now been used to engineer nonribosomally synthesizedantitumor drugs, epirubicin (4-epidoxorubicin). Over
peptide antibiotics by targeted mutation and precursor-last few years, combinatorial biosynthesis has been
directed biosynthesis [13] (Hojati et al., this issue [19]).shown to be a powerful tool for modifying several natural
Two groups lead by Smith and Micklefield report thecompounds with highly diverse structure [5].
generation of novel CDA (calcium-dependent antibiotic)An alternative technique, which has also widely been
derivatives. It is well established that CDA is producedused, is to feed altered natural product precursors to
by the model streptomycete S. coelicolor [14]. CDA be-microorganisms, which may subsequently be incorpo-
longs to the group of acidic lipopeptide antibiotics thatrated in a product of interest. However, one drawback of
consist of 11 amino acids to which a lipid part has beenthis approach is that since, under normal circumstances,
attached [15]. Although the accurate target of CDA isthe alternative precursors must compete with the natural
not yet known, antibiotics showing structural similarity,precursors, the yield of novel derivatives is rather low.
like daptomycin or friulimicin, are of great importanceThis disadvantage can be overcome by blocking the
because they potently inhibit bacterial cell wall synthe-synthesis of the natural precursor, either by mutating
sis. Albeit undefined, this unique mechanism of actionkey genes [6] in the respective synthetic pathway or by
is the reason that CDA-related drugs may become soadding specific inhibitors of biosynthetic enzymes.
important in treating infections from severe antibiotic resis-To date, these manipulations were rather heavy
tant pathogens, such as methicillin-resistant Staphylococ-handed, since the inhibitors often influence other parts
cus aureus strains (MRSA) and vancomycin-resistant en-of the pathway, and the mutations were obtained by
chemical or UV mutagenesis, which led to additional terococci (VRE).
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